TRIFECTA CELL INFUSION
LIVE

Serial Number

99064085

Owner

ImmunityBio, Inc.

Attorney

Michael J. McCue

Filing Date

Mar 3, 2025

Add to watchlist:

No watchlists yet
View on USPTO

TRIFECTA CELL INFUSION Trademark

Serial Number: 99064085

TRIFECTA CELL INFUSION is a trademark filed by ImmunityBio, Inc. on March 3, 2025. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

ImmunityBio, Inc. (6 trademarks)

3530 John Hopkins Court
San Diego, CA 92121

Entity Type: 03

Trademark Details

Filing Date

March 3, 2025

Registration Date

Not Registered

Goods & Services

pharmaceutical preparations and substances for the treatment of human diseases and animal diseases, namely, bladder cancer, prostate cancer, blood cancers, brain cancers, lung cancer, liver cancer, colorectal cancer, pancreatic cancer, non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, lymphopenia, genetic diseases, Lynch syndrome, HIV, papillomavirus, infections, viral infections, respiratory infections and blood infections, autoimmune diseases, infectious diseases and cancer for scientific, clinical, medicinal, therapeutic, and diagnostic purposes; pharmaceutical preparations and substances for the prevention and treatment of human diseases and animal diseases, namely, bladder cancer, prostate cancer, blood cancers, brain cancers, lung cancer, liver cancer, colorectal cancer, pancreatic cancer, non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, lymphopenia, genetic diseases, Lynch syndrome, HIV, papillomavirus, infections, viral infections, respiratory infections and blood infections, autoimmune diseases, infectious diseases and cancer; pharmaceutical and biological preparations for use in targeted immunotherapy for the treatment of human diseases and animal diseases, namely, bladder cancer, prostate cancer, blood cancers, brain cancers, lung cancer, liver cancer, colorectal cancer, pancreatic cancer, non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, lymphopenia, genetic diseases, Lynch syndrome, HIV, papillomavirus, infections, viral infections, respiratory infections and blood infections, autoimmune diseases, infectious diseases and cancer; pharmaceutical preparations and substances containing autologous or allogeneic cells for the treatment of human diseases and animal diseases in the nature of cancer, non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, autoimmune diseases and infectious diseases; biologic in the nature of pharmaceutical preparations for the treatment of autoimmune diseases, infectious diseases, and cancer, namely, cell-derived preparations, cell therapies, monoclonal antibodies, cytokines, immune modulators, antibodies, fusion proteins, peptide and cytokine biologics, and natural killer cell derived preparations for clinical, medicinal, therapeutic, and veterinary purposes; kits comprising cell cultures being biological preparations for medical purposes and reagents for medical use and also including printed instructions, for use in the treatment and prevention of bladder cancer, prostate cancer, blood cancers, brain cancers, lung cancer, liver cancer, colorectal cancer, pancreatic cancer, non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, lymphopenia, genetic diseases, Lynch syndrome, HIV, papillomavirus, infections, viral infections, respiratory infections and blood infections, non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, autoimmune diseases, infectious diseases, and cancer for clinical, medicinal, therapeutic and veterinary purposes; all of the aforementioned excluding preparations and substances used in connection with implant material

Filing History

SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jun 23, 2026 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Nov 17, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Nov 17, 2025 GNSL
SUSPENSION LETTER WRITTEN
Nov 17, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 27, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 27, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 27, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 7, 2025 GNRN
NON-FINAL ACTION E-MAILED
Aug 7, 2025 GNRT
NON-FINAL ACTION WRITTEN
Aug 7, 2025 CNRT
ASSIGNED TO EXAMINER
Aug 5, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 3, 2025 NWOS
APPLICATION FILING RECEIPT MAILED
Mar 3, 2025 MAFR
NEW APPLICATION ENTERED
Mar 3, 2025 NWAP